GlassScriptPhysician profile
Matthew Laroe
NPI 1598290454
$7,356.87
in general payments reported to CMS, 2019-2025
40 companies · $2,015 in 2025
The $2,015 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $829 · 2023: $1,946 · 2024: $2,567 · 2025: $2,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,527.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,301.59 | 2022-2025 | Omnipod |
| Novo Nordisk INC | $1,084.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,014.67 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $415.01 | 2022-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $296.20 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.95 | 2022-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $230.41 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $210.38 | 2022-2024 | |
| Ibsa Pharma INC. | $205.53 | 2022-2024 | Tirosint, Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $184.86 | 2022-2025 | Unithroid |
| Radius Health, INC. | $173.11 | 2023-2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $164.88 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Antares Pharma, INC. | $157.31 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $157.00 | 2022-2025 | |
| Tolmar, INC. | $123.52 | 2023-2025 | Jatenzo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $97.00 | 2023-2025 | Cequr Simplicity |
| Dexcom, INC. | $96.32 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $88.20 | 2022-2024 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $86.53 | 2022-2023 | Tepezza |
| Beta Bionics, INC. | $86.26 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Halozyme INC | $80.98 | 2023 | |
| Lifescan, INC. | $80.62 | 2022-2023 | |
| Tandem Diabetes Care, INC. | $69.36 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Acella Pharmaceuticals, LLC | $66.59 | 2023 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $65.46 | 2022-2024 | |
| Sequel Med Tech, LLC | $64.80 | 2025 | Twiist |
| Mannkind Corporation | $62.08 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $54.84 | 2023-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $53.53 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $52.44 | 2023-2024 | Nexletol |
| Soleno Therapeutics, INC. | $40.73 | 2025 | Vykat Xr |
| Boston Scientific Corporation | $40.34 | 2024-2025 | General - Pain Management |
| Corcept Therapeutics | $37.21 | 2024 | Korlym |
| Abbvie INC. | $30.18 | 2024 | |
| Merck Sharp & Dohme LLC | $26.70 | 2022 | |
| Verity Pharmaceuticals INC. | $24.50 | 2024 | Tlando |
| Amarin Pharma, INC. | $20.65 | 2022 | |
| Astellas Pharma US INC | $18.69 | 2023 | Veozah |
| Medtronic, INC. | $14.32 | 2025 | Intellis Adaptivestim |
| Averitas Pharma INC. | $12.77 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Laroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.